Remove Milwaukee Remove Revenue Remove Startup
article thumbnail

Term-sheets and Valuations: Thinking about Negotiations - Startups.

Tim Keane

Startups and angels: Along the way to success. « Power of Angel Investing in Milwaukee | Main. 3]   However, if they are built bottom up, they demonstrate and make explicit a range of business model assumptions the entrepreneur is using to think about his business and its revenue model.

article thumbnail

2011 Valuation Survey of North American Angel Groups

Gust

To provide some reference points, I surveyed thirteen angels groups in North American to determine their recent experience in negotiating the pre-money valuation of pre-revenue companies. See the 2010 data reported here: Current Pre-money Valuations of Pre-revenue Companies. Pre-money Valuation of Pre-revenue Companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Are Investors Being Unreasonable? - Startups and angels: Along the.

Tim Keane

Startups and angels: Along the way to success. from the August 20th Milwaukee Journal Sentinel.  from the August 20th Milwaukee Journal Sentinel.  up to $10MM in revenue.  from the August 20th Milwaukee Journal Sentinel.  up to $10MM in revenue.  Funding startups.

article thumbnail

When All Else Fails.Manipulate The Data - Startups and angels.

Tim Keane

Startups and angels: Along the way to success. I saw that on a t-shirt worn by a bartender at the Milwaukee Irish Fest last night. As the venture progresses from financing to revenue (whether financed by an investor or the entrepreneur) that first big, critical issue has to be the first miss on projections. Funding startups.

article thumbnail

2012 Valuation Survey of Angel Groups

Gust

This summer I conducted our third annual survey of the pre-money valuation of pre-revenue companies recently funded by angel groups in North America. For the first time, we asked for data from specific business sectors, as follows: All pre-revenue deals. Pre-revenue life Science, biotech and medical device deals. Average: 2.96.